114 related articles for article (PubMed ID: 38829041)
1. Early extracorporeal photopheresis treatment is associated with better survival in patients with chronic or recurrent acute lung allograft dysfunction.
Gautschi F; Vogelmann T; Ortmanns G; Knörr F; Steinack C; Hage R; Nägeli M; Schuurmans MM
J Clin Apher; 2024 Jun; 39(3):e22128. PubMed ID: 38829041
[TBL] [Abstract][Full Text] [Related]
2. Cessation of extracorporeal photopheresis in chronic lung allograft dysfunction: effects on clinical outcome in adults.
Robinson CA; Huber L; Murer C; Schuurmans M; Kohler M; Hofbauer G; Benden C
Swiss Med Wkly; 2017; 147():w14429. PubMed ID: 28488260
[TBL] [Abstract][Full Text] [Related]
3. Outcomes Following Extracorporeal Photopheresis for Chronic Lung Allograft Dysfunction Following Lung Transplantation: A Single-Center Experience.
Vazirani J; Routledge D; Snell GI; Watson D; Paraskeva M; Westall GP; Harrison SJ
Transplant Proc; 2021; 53(1):296-302. PubMed ID: 33039145
[TBL] [Abstract][Full Text] [Related]
4. Lung transplant recipients on long-term extracorporeal photopheresis.
Isenring B; Robinson C; Buergi U; Schuurmans MM; Kohler M; Huber LC; Benden C
Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28653398
[TBL] [Abstract][Full Text] [Related]
5. Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK).
Fisher AJ; White M; Goudie N; Kershaw A; Phillipson J; Bardgett M; Lally J; Bevin-Nicholls A; Chadwick T; Bryant A; Russell S; Smith H; Frisby L; Errington R; Carby M; Thompson R; Santhanakrishnan K; Parmar J; Lordan JL; Vale L; Hancock H; Exley C; Gennery AR; Wason JM
BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38724453
[TBL] [Abstract][Full Text] [Related]
6. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.
Benden C; Haughton M; Leonard S; Huber LC
J Heart Lung Transplant; 2017 Sep; 36(9):921-933. PubMed ID: 28662986
[TBL] [Abstract][Full Text] [Related]
7. A European Multi-Center Analysis of Extracorporeal Photopheresis as Therapy for Chronic Lung Allograft Dysfunction.
Benazzo A; Bagnera C; Ius F; Del Fante C; Gottlieb J; Hoetzenecker K; Meloni F; Jaksch P; Greer M
Transpl Int; 2023; 36():11551. PubMed ID: 38282747
[TBL] [Abstract][Full Text] [Related]
8. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients.
Greer M; Dierich M; De Wall C; Suhling H; Rademacher J; Welte T; Haverich A; Warnecke G; Ivanyi P; Buchholz S; Gottlieb J; Fuehner T
Am J Transplant; 2013 Apr; 13(4):911-918. PubMed ID: 23406373
[TBL] [Abstract][Full Text] [Related]
9. Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction.
Moniodis A; Townsend K; Rabin A; Aloum O; Stempel J; Burkett P; Camp P; Divo M; El-Chemaly S; Mallidi H; Rosas I; Fuhlbrigge A; Koo S; Goldberg HJ
J Heart Lung Transplant; 2018 Mar; 37(3):340-348. PubMed ID: 28431983
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Off-Line Extracorporeal Photochemotherapy in Patients with Chronic Lung Allograft Rejection Not Responsive to Conventional Treatment: A 10-Year Single-Centre Analysis.
Del Fante C; Scudeller L; Oggionni T; Viarengo G; Cemmi F; Morosini M; Cascina A; Meloni F; Perotti C
Respiration; 2015; 90(2):118-28. PubMed ID: 26112178
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of extracorporeal photopheresis to arrest bronchiolitis obliterans in lung allograft recipients was compared between two automated photopheresis instruments.
Chionis L; Grossman BJ; Hachem R; Commean P; Derfler MC; Vedantham S; Dodds K; Spitznagel E; Atkinson J; Despotis G
Transfusion; 2018 Dec; 58(12):2933-2941. PubMed ID: 30312482
[TBL] [Abstract][Full Text] [Related]
12. Validation of a post-transplant chronic lung allograft dysfunction classification system.
Van Herck A; Verleden SE; Sacreas A; Heigl T; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verbeken EK; Neyrinck AP; Van Raemdonck D; Verleden GM; Vos R
J Heart Lung Transplant; 2019 Feb; 38(2):166-173. PubMed ID: 30391199
[TBL] [Abstract][Full Text] [Related]
13. Extracorporeal photopheresis as second-line treatment therapy in life-threatening primary graft dysfunction following lung transplantation.
Robinson CA; Inci I; Naegeli M; Murer C; Schuurmans MM; Urosevic-Maiwald M; Schüpbach R; Weder W; Benden C
Pediatr Transplant; 2018 May; 22(3):e13145. PubMed ID: 29380491
[TBL] [Abstract][Full Text] [Related]
14. Factors Associated With Mortality and Response to Extracorporeal Photopheresis in Lung Allograft Recipients With Bronchiolitis Obliterans Syndrome.
Karnes HE; Schindler EI; Morrell M; Hachem RR; Berman K; Vedantham S; Atkinson J; Spitznagel E; Despotis GJ
Transplantation; 2019 May; 103(5):1036-1042. PubMed ID: 30130331
[TBL] [Abstract][Full Text] [Related]
15. Assessing treatment outcomes in CLAD: The Hannover-extracorporeal photopheresis model.
Greer M; Liu B; Magnusson JM; Fuehner T; Schmidt BMW; Deluca D; Falk C; Ius F; Welte T
J Heart Lung Transplant; 2023 Feb; 42(2):209-217. PubMed ID: 37071121
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal lung function measurements in single lung transplant recipients with chronic lung allograft dysfunction.
Leuschner G; Lauseker M; Howanietz AS; Milger K; Veit T; Munker D; Schneider C; Weig T; Michel S; Barton J; Meiser B; Dinkel J; Neurohr C; Behr J; Kneidinger N
J Heart Lung Transplant; 2020 Nov; 39(11):1270-1278. PubMed ID: 32917480
[TBL] [Abstract][Full Text] [Related]
17. Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction.
; Hage CA; Klesney-Tait J; Wille K; Arcasoy S; Yung G; Hertz M; Chan KM; Morrell M; Goldberg H; Vedantham S; Derfler MC; Commean P; Berman K; Spitznagel E; Atkinson J; Despotis G
Transfus Med; 2021 Aug; 31(4):292-302. PubMed ID: 33955079
[TBL] [Abstract][Full Text] [Related]
18. Disease progression in patients with the restrictive and mixed phenotype of Chronic Lung Allograft dysfunction-A retrospective analysis in five European centers to assess the feasibility of a therapeutic trial.
Gottlieb J; Verleden GM; Perchl M; Valtin C; Vallee A; Brugière O; Bravo C
PLoS One; 2021; 16(12):e0260881. PubMed ID: 34941934
[TBL] [Abstract][Full Text] [Related]
19. Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction.
Sato M; Waddell TK; Wagnetz U; Roberts HC; Hwang DM; Haroon A; Wagnetz D; Chaparro C; Singer LG; Hutcheon MA; Keshavjee S
J Heart Lung Transplant; 2011 Jul; 30(7):735-42. PubMed ID: 21419659
[TBL] [Abstract][Full Text] [Related]
20. Impact of chronic lung allograft dysfunction, especially restrictive allograft syndrome, on the survival after living-donor lobar lung transplantation compared with cadaveric lung transplantation in adults: a single-center experience.
Sugimoto S; Yamamoto H; Kurosaki T; Otani S; Okazaki M; Yamane M; Toyooka S; Oto T
Surg Today; 2019 Aug; 49(8):686-693. PubMed ID: 30790054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]